The CHA2DS2-VASc score predicts long-term outcomes in patients with non-valvular atrial fibrillation who initiate apixaban after acute ischemic stroke due to large vessel occlusion.
Does the pre-stroke CHA2DS2-VASc score predict long-term outcomes after large vessel occlusion in patients with non-valvular atrial fibrillation?
The study investigates the predictive value of the CHA2DS2-VASc score for long-term outcomes in patients with non-valvular atrial fibrillation and large vessel occlusion stroke.
Absolute Event Rate: 0% vs 0%
BACKGROUND: The CHA METHODS: Patients with AF who were started on oral anticoagulant apixaban within 14 days of the onset of AIS due to LVO from a multicenter prospective observational study were included. They were divided into three groups based on the pre-stroke CHA RESULTS: The analysis included 632 patients (mean age 77.4 years, 48.1% female; median CHA CONCLUSION: The CHA
Ohara et al. (Tue,) reported a other. The CHA2DS2-VASc score predicts long-term outcomes in patients with non-valvular atrial fibrillation who initiate apixaban after acute ischemic stroke due to large vessel occlusion.